Mumbai, Oct. 4 -- The product is bioequivalent to Novo Nordisk Inc.'s Victoza Injection, 18 mg/3 mL (6 mg/mL), and is indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

The reference drug, Victoza, has an estimated annual U.S. market sale of approximately $350 million (IQVIA MAT Aug 2025).

Spiro Gavaris, President - U.S. Generics, Lupin, said, "We are pleased to launch Liraglutide Injection in the U.S. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients."

In an another exchange filing, Lupin dis...